An announcement from Qiagen ( (QGEN) ) is now available.
QIAGEN N.V. announced a transaction involving the release and grant of Restricted Stock Units (RSUs) to Ross Levine, a member of its administrative or supervisory body. The transaction included the release of 5,656 RSUs granted in 2020 and 2,792 RSUs granted in 2022, with a subsequent receipt of 3,803 common shares after covering related expenses. Additionally, 5,990 new RSUs were granted. This transaction reflects QIAGEN’s ongoing commitment to its share option programs, potentially impacting its stock market performance and stakeholder interests.
More about Qiagen
QIAGEN N.V. is a company operating in the biotechnology industry, primarily focused on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is listed on various stock exchanges including Frankfurt, NYSE, and SIX, and is headquartered in Venlo, Netherlands.
YTD Price Performance: -13.75%
Average Trading Volume: 1,094,687
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.36B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.